🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsRetatrutide & Triple AgonistsTRIUMPH-2 obesity without diabetes — my results so far

TRIUMPH-2 obesity without diabetes — my results so far

anna.melb_AU Sat, Jan 10, 2026 at 1:46 PM 23 replies 1,368 viewsPage 1 of 5
anna.melb_AU
Member
678
2,890
Apr 2024
Melbourne, AU
Jan 10, 2026 at 1:46 PM#1

Sceptical rather than excited about the triple agonist, and I would like somebody to talk me out of the scepticism with data rather than enthusiasm.

The question I want answered is why adding glucagon agonism to an anti-obesity drug is not self-defeating, given that glucagon raises blood glucose.

If the honest answer is that nobody knows, that is a useful answer and I would rather have it.

27 22DerekSJ_a1c, paige_pharma, emma_london and 24 others
Reply Quote Save Share Report
SarahChen_PharmD
VIP Member
4,567
22,341
Dec 2023
San Diego, CA
Jan 10, 2026 at 2:01 PM#2

Taking the question as asked, rather than the general version of it. The honest answer is that the effect is real, the magnitude is contested, and the individual variation is larger than either. Those three things can all be true at once, and most arguments here are two people holding different parts of that.

26 21NurseKim_ATL, paul_denver, TinaHashiRN and 23 others
Reply Quote Save Share Report
fiona_glasgow
Member
312
1,345
Aug 2024
Glasgow, UK
Jan 10, 2026 at 2:16 PM#3
SarahChen_PharmD said:
The honest answer is that the effect is real, the magnitude is contested, and the individual variation is larger than either.

Agreeing with SarahChen_PharmD, and the qualification matters more than the agreement. The glucagon component looks paradoxical and is not. Glucagon receptor agonism raises energy expenditure and drives hepatic fatty-acid oxidation, and its hyperglycaemic tendency is offset by the GLP-1 arm's insulin secretagogue effect. Net result: intake down from GLP-1/GIP, expenditure up from glucagon, glycaemia neutral or improved. It is a balancing act, and it is why the liver-fat results are the most interesting part of the dataset.

25 20KevinCompounds, TirzTom, TrialTracker_MD and 22 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
WendyG_ATL
Member
1,023
5,678
Apr 2024
Georgia
Jan 10, 2026 at 2:31 PM#4
anna.melb_AU said:
Sceptical rather than excited about the triple agonist, and I would like somebody to talk me out of the scepticism with data rather than enthusiasm.

This is my experience too, for whatever a second data point is worth.

24 19AttorneyGrant, DebRD_ATL, KristenIndy and 21 others
Reply Quote Save Share Report
claudia_zurich
Member
389
1,678
Jul 2024
Zurich, CH
Jan 10, 2026 at 3:48 PM#5

From the other side of the consultation, briefly. It helps to ask what evidence would change your mind before you look at any. If nothing would, the discussion is not about evidence, and it is better to say so early than to spend nine posts discovering it.

23 18kevin_tulsa, Dr.PainCLE, mike_mealprep and 20 others
Reply Quote Save Share Report
1235

Similar Threads

TRIUMPH-3 topline results — 24.2% body weight loss at 48 weeks10 replies
Retatrutide mechanism: GLP-1/GIP/glucagon triple agonism explained5 replies
Retatrutide Phase 2 dose-response analysis — optimal dose range10 replies
Glucagon receptor agonism and hepatic lipid oxidation — MASH implications13 replies
Retatrutide vs tirzepatide — dual vs triple agonist comparison22 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register